Skip to main content
letter
. 2016 Oct;101(10):e427–e428. doi: 10.3324/haematol.2016.150714

Figure 1.

Figure 1.

A. Kaplan-Meir estimate of the survival of MDS patients with HMA failure classified according to MDS consortium HMA failure score. B. Subset analysis for patients treated with best supportive care. Survival is expressed in months and is defined from the time of HMA failure to last follow-up or death. HR: high-risk; LR: low-risk; UNK: unknown; HMA: hypomethylating agents; MDS: myelodysplastic syndrome.